Retatrutide Phase 3 Triumph Trials Completion Dates May 2026 Impact On Nda

Eli Lilly's investigational drug retatrutide is making waves in obesity treatment, with its phase 3 TRIUMPH trials approaching critical completion dates in May 2026[2] that could shape the path to FDA approval. Key pivotal studies like TRIUMPH-1 and TRIUMPH-3 are slated to finish around this time[2], providing essential data for a New Drug Application (NDA) submission expected in late 2026 or early 2027. These milestones highlight retatrutide's potential as a triple hormone agonist offering superior weight loss compared to current options, and the retatrutide phase 3 triumph trials completion dates may 2026 impact on nda will be pivotal for regulatory progress.

Introduction to Retatrutide and the TRIUMPH Phase 3 Program

What is Retatrutide? A Triple Hormone Receptor Agonist

Retatrutide, developed by Eli Lilly, targets three key hormones: GIP, GLP-1, and glucagon. This unique triple action helps control blood sugar, slow digestion, and boost energy use, leading to significant weight loss. Unlike single or dual agonists like semaglutide (Wegovy) or tirzepatide (Zepbound), retatrutide's approach may deliver even better results for obesity and related conditions.

Administered as a once-weekly injection, it has shown promise in early trials. Phase 2 data revealed up to 24.2% body weight reduction at 48 weeks (NEJM Phase 2)[1]. Now, phase 3 testing confirms its potential in real-world patient groups.

Overview of the TRIUMPH Clinical Trials for Obesity and Comorbidities

The TRIUMPH program includes seven phase 3 trials testing retatrutide in over 2,000 participants with obesity, type 2 diabetes, knee osteoarthritis, cardiovascular disease, and more. These studies evaluate weight loss, safety, and benefits for comorbidities. Pivotal trials like TRIUMPH-1 and TRIUMPH-2 focus on broad obesity populations, while others target specific risks.

Trials use doses up to 12 mg after gradual escalation to minimize side effects. Endpoints include percent weight loss, A1C reductions, and quality-of-life improvements. Full results from 2026 readouts will support regulatory filings (ClinicalTrials.gov)[2].

Why May 2026 Matters for Retatrutide Phase 3 Triumph Trials Completion Dates

May 2026 marks the estimated wrap-up for TRIUMPH-1 (pivotal obesity trial, primary completion Q2 2026) and TRIUMPH-3 (cardiovascular outcomes)[2]. These dates align with the retatrutide phase 3 triumph trials completion dates may 2026 impact on nda, as they provide core efficacy and safety data. Delays here could push back Lilly's submission plans.

Analysts see this as a turning point for obesity drugs. Successful readouts may enable dual indications for obesity and diabetes. Investors watch closely, with peak sales forecasts exceeding $15 billion by 2031 (Eli Lilly Investor Relations).

Current Status of Retatrutide Phase 3 TRIUMPH Trials

The retatrutide phase 3 triumph trials completion dates may 2026 impact on nda depends on timely readouts from key studies like TRIUMPH-1 and TRIUMPH-3. Here's a snapshot of the program's progress:

Trial	Indication	Primary Completion	Study Completion	Status
TRIUMPH-1	Obesity (pivotal)	Q2 2026 (Apr-Jun)	May 2026	Ongoing
TRIUMPH-2	Obesity (replication)	Q3 2026	Late 2026	Ongoing
TRIUMPH-3	Obesity + CVD	Q2 2026	May 2026	Ongoing
TRIUMPH-4	Obesity + knee OA	Dec 2025	Completed	Topline released
TRIUMPH-5	Type 2 diabetes	Q3 2026	Late 2026	Ongoing

TRIUMPH-1: Pivotal Obesity Trial Primary Completion in Q2 2026

TRIUMPH-1 (NCT05929066)[2] is the cornerstone trial for obesity in adults without diabetes. It enrolls thousands to test doses from 2 mg to 12 mg over 80+ weeks. Primary completion is expected in Q2 2026 (April-June), with full data soon after.

This trial's results will prove if retatrutide meets FDA standards for at least 5% more weight loss than placebo. For deeper insights, see the TRIUMPH-1 trial results. Positive outcomes could accelerate NDA prep. Compare to tirzepatide phase 3 results.

TRIUMPH-3: Cardiovascular Disease Trial Wrapping Up May 2026

TRIUMPH-3 targets patients with obesity and established cardiovascular disease, enrolling about 2,300 participants since 2023. Study completion is projected for May 2026, focusing on CV safety and risk factor improvements like blood pressure and lipids. This data is vital for labeling claims beyond weight loss.

Details on CV outcomes are available in the TRIUMPH-3 cardiovascular outcomes article. It addresses FDA requirements for heart safety in chronic-use drugs. See also semaglutide CVOT data.

TRIUMPH-4 Results: Already Completed with Record 28.7% Weight Loss

TRIUMPH-4 wrapped up in December 2025, testing retatrutide in 445 people with obesity and knee osteoarthritis over 68 weeks[3]. Participants lost a mean 28.7% body weight (26.6% placebo-adjusted) at the 12 mg dose[3]—the highest in any phase 3 obesity trial. It also cut knee pain by 75% and boosted physical function.

Secondary benefits included better blood pressure and CV markers. Discontinuation rates were 12-18% vs. 4% placebo, mostly due to GI issues. This sets a high bar for competitors (Lilly Press Release)[3].

Other Key Trials: TRIUMPH-2, TRIUMPH-5, and Beyond

TRIUMPH-2, the obesity replication trial, expects Q3 2026 readout to confirm TRIUMPH-1. TRIUMPH-5 for type 2 diabetes follows suit in Q3 2026, alongside TRANSCEND-T2D-1 (positive topline March 2026 with A1C and weight drops). Additional studies cover sleep apnea and maintenance dosing, all finishing by year-end.

These build a full dataset for broad approval. Over 7 trials ensure robust evidence across populations. Related: Eli Lilly obesity pipeline.

Efficacy Highlights from Retatrutide Phase 3 Data

Weight Loss Achievements: Up to 28.7% in TRIUMPH-4 at 68 Weeks

TRIUMPH-4's 28.7% mean weight loss at 68 weeks[3] outpaces tirzepatide's 20-22% and semaglutide's 15-17%. Weight continued dropping without plateau, thanks to glucagon's fat-burning effect. Placebo groups lost just 2.1%.

High responders (over 30% loss) were common at top doses. This positions retatrutide as a game-changer for severe obesity.

Dose	Weight Loss (Absolute)	Placebo-Adjusted
12 mg	28.7%	26.6%
9 mg	~25%	~23%
Placebo	2.1%	-

Benefits for Knee Osteoarthritis, Type 2 Diabetes, and CV Risk Factors

In TRIUMPH-4, knee pain dropped 75%, with major gains in walking and daily activities. Related trials show 2% A1C reductions in diabetes patients, matching or beating dulaglutide. CV benefits include lower cholesterol, blood pressure, and inflammation markers.

• Knee OA: 75% pain reduction, improved WOMAC scores
• T2D: Up to 2% A1C drop (TRANSCEND-T2D-1)
• CV: Systolic BP -10 mmHg, LDL -15%

These comorbidities affect millions; retatrutide could treat root causes holistically. Long-term data will clarify durability.

Comparison to Phase 2 Results and GLP-1 Competitors

Phase 2 hit 24.2% loss at 48 weeks[1], but phase 3 extended to 28.7% at 68 weeks[3]—proving sustained efficacy. Versus GLP-1s like Ozempic (15%) or Mounjaro (22%), retatrutide leads by 5-10%. Triple agonism adds liver fat reduction and energy expenditure.

Head-to-head trials are pending, but early signs suggest superiority. See GLP-1 agonists comparison.

Safety Profile and Side Effects in TRIUMPH Trials

Common Gastrointestinal Side Effects: Nausea, Diarrhea, and Vomiting

Most side effects are GI-related: nausea (40-50%), diarrhea (30%), vomiting (20-25%), peaking during dose ramps (weeks 1-16). They are mild-moderate, decrease over time, and occur less with slow titration. Lower doses cut events by 20-30%.

• Nausea: Peaks week 5, resolves by week 24
• Diarrhea: Dose-related, manageable with hydration
• Similar to other incretins, but manageable with diet and anti-nausea meds

Emerging Safety Signal: Dysesthesia in High-Dose Patients

Dysesthesia—tingling or abnormal skin sensations—affected 20% at 12 mg in TRIUMPH-4[3], higher than placebo. It's dose-related and mostly mild, but under close watch for long-term impact. No serious cases reported yet.

Learn more about dysesthesia causes and management. Lilly is monitoring in ongoing trials. Potential link to glucagon effects on nerves.

Heart Rate Changes, Discontinuation Rates, and Long-Term Monitoring

Heart rate rose 10-15 bpm early, then stabilized or declined by week 24. No increased CV events seen. Discontinuations hit 12-18% from AEs vs. 4% placebo; see Phase 3 discontinuation rates.

Two-year data pending; CV outcomes from TRIUMPH-3 critical. Overall, profile aligns with class but needs full readout. No liver/kidney signals; gallbladder events low.

May 2026 TRIUMPH Trials Completions and NDA Impact

The retatrutide phase 3 triumph trials completion dates may 2026 impact on nda cannot be overstated, as TRIUMPH-1 and TRIUMPH-3 provide the backbone for approval.

How May 2026 Completions (TRIUMPH-1 and TRIUMPH-3) Shape NDA Prep

The retatrutide phase 3 triumph trials completion dates may 2026 impact on nda hinges on TRIUMPH-1 (Q2 primary) and TRIUMPH-3 (May full)[2]. These deliver pivotal efficacy and CV safety data FDA demands. Analysis takes 3-6 months post-completion.

Without them, submission stalls. They enable obesity labeling with CV claims. Lilly's team is preparing integrated summaries now.

Full Program Requirements: All Seven Trials Needed for Submission

FDA requires two pivotal obesity trials (TRIUMPH-1/2), plus safety in comorbidities. All seven TRIUMPH studies must succeed for comprehensive NDA. Diabetes data from TRIUMPH-5/TRANSCEND could add indications.

• Pivotal: Efficacy replication
• Supportive: Comorbidities (OA, CVD, T2D)
• Safety: Long-term AE monitoring

Partial filings unlikely; full package targeted for Q4 2026.

Expected NDA Filing Timeline: Q4 2026 to Q1 2027

Post-May 2026, Lilly compiles data for NDA by late 2026/early 2027. This assumes clean results. Priority review possible if breakthrough status granted, shaving months (FDA Guidance).

Scenarios:

• Best case: Q3 2026 NDA, 6-month review
• Base: Q4 2026 NDA, 10 months
• Delay: 2027 NDA if safety issues

FDA Approval Timeline and Legal Status Post-TRIUMPH Readouts

Projected PDUFA Date and Standard 10-Month Review

NDA filing Q4 2026 leads to PDUFA in mid-late 2027 (10-month standard review). Best case: early 2027 submit, Q3 PDUFA. See the projected PDUFA date for details.

Launch could follow by 2028. Advisory committee unlikely unless safety flags. Manufacturing scale-up key for approval.

Current Legal Status: Investigational, Not FDA-Approved

Retatrutide remains investigational—no NDA filed, not approved[4]. Available only via trials (current FDA approval status). Compounded versions risky; FDA warns against unapproved copies (FDA Compounding Alert)[4].

Patients: Join trials or waitlists. No expanded access yet.

Factors Influencing Priority Review or Delays

Safety signals like dysesthesia could trigger requests for more data. Replication success in TRIUMPH-2 key. EMA/TGA may align, with EU approval 2027-2028.

• Positive: Superior efficacy, unmet need
• Risks: AE profile, manufacturing
• Global: EMA parallel, TGA expedited

Global Approval Forecasts: EMA, TGA, and Beyond

EMA review parallels FDA; TGA faster for obesity drugs. Japan/China trials ongoing. Harmonized data speeds multi-market entry. Potential 2027 launches in Australia/EU.

Risks, Challenges, and What to Watch For

Potential Safety Hurdles like Dysesthesia and GI Events

Dysesthesia may cap high doses or need warnings. Severe GI could limit use in elderly. Long-term CV from TRIUMPH-3 pivotal.

• Monitor: 2-year extensions
• Mitigation: Dose adjustments
• Impact: Labeling restrictions possible

Replication Requirements for Pivotal Trials

TRIUMPH-2 must match TRIUMPH-1 or risk rejection. FDA insists on consistent efficacy across studies. Statistical powering ensures reliability.

TRANSCEND-T2D Program and Dual Indications

T2D data supports combo label, but separate review possible. Watch for March 2026 topline expansions. Dual approval boosts market.

Patient Access: Clinical Trials and Compounding Warnings

Enroll via ClinicalTrials.gov; post-approval, insurance key. Avoid compounding due to purity risks. Key risk: NDA complete response letter risks if data gaps emerge.

Watch obesity drug insurance coverage 2026.

Conclusion: The Path Forward for Retatrutide NDA

Summary of May 2026 Milestones and NDA Implications

May 2026 closes TRIUMPH-1/3, fueling Q4 2026 NDA amid strong TRIUMPH-4 data. The retatrutide phase 3 triumph trials completion dates may 2026 impact on nda underscores a 2027 approval shot. Watch readouts for safety confirms. Overall program positions retatrutide for transformative role.

Optimistic Projections: $15B Sales Potential by 2031

With unmatched 28%+ loss and broad benefits, retatrutide eyes blockbuster status. Analysts project $15.6B peak sales, transforming obesity care. Patients await transformative therapy if hurdles cleared (GlobalData Forecast).

References

1. NEJM: Retatrutide Phase 2 Trial Results
2. ClinicalTrials.gov: TRIUMPH-1 (NCT05929066)
3. Eli Lilly: TRIUMPH-4 Phase 3 Trial Press Release
4. FDA: Alert on Compounded GLP-1 Drugs
5. ClinicalTrials.gov: TRIUMPH-3 Cardiovascular Outcomes Trial